Fig. 1.

Expression of the LMS predicts for increased risk of distant failure selectively in the lung and is associated with other markers of poor prognosis. (A) Kaplan–Meier curves representing the probability of cumulative lung metastasis-free survival for the MSK (Left) and combined NKI-295/EMC-344 (Right) cohorts. (B) Distribution of site(s) of first distant failure (simultaneous metastasis sites included) in the NKI-295/EMC-344 cohort according to LMS status. The P value for the difference in distribution for lung metastasis is shown and was calculated by a χ² test. Patients with LMS⁺ primary tumors are shown in red, and LMS⁻ tumors are in blue. (C) Hierarchical clustering was performed on the NKI-295 cohort with the indicated pathological and genomic markers consisting of the 70-gene prognosis signature (9, 10) (NKI 70), 16-gene recurrence score (18) (Rec score), molecular subtype (19) (Subtype), and wound response signature (17) (Wound). The legend for the color codes for each marker is shown. The luminal A, luminal B, and normal-like subtypes were grouped together as “Other” and consist of 5.8, 1.9, and 7.7% of LMS⁺ tumors, respectively.